Välkommen till slmf.se
Dessa sidor är till för Svensk Lungmedicinsk Förenings medlemmar och riktar sig endast till hälso- och sjukvårdspersonal
SPARC
SPARC (Swedish Pulmonary Alliance for Research Collaboration) är ett forskningsnätverk under SLMF för att stödja och genomföra svenska kliniska multicenterstudier inom lungmedicin.
Vid frågor eller intresse, kontakta: sparc@slmf.se
Studier
BRONCHIOLE
Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE
Academic, pragmatic, randomized, controlled, trial of added metoprolol compared with usual care only in people with chronic obstructive pulmonary disease (COPD) who do not have any cardiovascular indication for treatment with beta blocker. Primary composite outcome is cardiac event, exacerbation or death up to one year.
Coordinating Investigator: Josefin Sundh, Region Örebro County.
Protocol article, doi: 10.1186/s13063-019-3907-1
ClinicalTrials.gov, ID: NCT03566667
HiLOT
Effect of HIgh-flow Therapy in Long-term Oxygen Therapy
A multicenter, registry-based, randomized clinical trial of added high-flow oxygen therapy during nighttime compared with usual care (low-flow oxygen therapy) alone in patients on long-term oxygen therapy due to COPD or interstitial lung disease (ILD). Primary composite outcome is time to all-cause hospitalization or death up to one year. The trial is conducted in collaboration with ResMed.
Coordinating Investigator: Magnus Ekström, Region Skåne.
Protocol article, doi: 10.1186/s13063-026-09488-8
ClinicalTrials.gov, ID: NCT06247397
MORE-B
Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial
Pragmatic, multicenter, double-blind, N-of-1, randomized clinical trial on the effect of morphine (up to 10mg) versus placebo given as subcutaneous injection for breathlessness at rest in adults with severe serious life-limiting disease and resting breathlessness. Subjects can participate for up to eight randomized, blinded, treatment doses. Primary outcome is change from baseline in breathlessness intensity at 60 minutes after the treatment dose. Secondary outcomes include other symptoms, safety measures, and adverse drug reactions. The trial is conducted in collaboration between respiratory and palliative care units.
Coordinating Investigator: Magnus Ekström, Region Skåne.
EU Trial Number: 2026-525838-32-00
RAPIDLY
RAPIDLY – the Robot-assisted plication in diaphragmatic paralysis study
A multicenter prospective observational cohort study of patients with symptomatic unilateral diaphragmatic paralysis scheduled for Robot Assisted Thoracic Surgery Plication at thoracic surgery clinics in five Swedish university hospitals (Gothenburg, Linköping, Lund, Umeå, and Uppsala). The study aims to assess the short- and long-term effects of plication on physical performance, breathlessness, lung function, gas exchange, and imaging outcomes.
Patients will be assessed preoperatively and postoperatively after one to three months and after one and three years.
Coordinating investigator: Andreas Palm, Region Uppsala
ClinicalTrials.gov, ID (to be announced)
REDOX
REgistry-based randomized controlled trial of treatment Duration and mortality in long-term OXygen therapy (REDOX)
Multicenter, phase IV, registry-Based, randomized controlled trial of long-term oxygen therapy prescribed for 24 hours/day compared with 15 hours/day. The trial is conducted using the Swedish Registry for Respiratory Failure (Swedevox). Primary composite outcome is time to all-cause hospitalization or death up to one year.
Coordinating Investigator: Magnus Ekström, Region Blekinge.
Protocol article, doi: 10.1186/s12890-019-0809-7.
ClinicalTrials.gov, ID: NCT03441204.
Main publication: https://pubmed.ncbi.nlm.nih.gov/39254466/
VALIDATE
Validation of International Standard Tests for Exertional Breathlessness (VALIDATE)
Multicenter validation study of the two clinical tests, the 3-minute stepping and walking tests, to assess the intensity of breathlessness at standardized level of exertion, in people with asthma, COPD, ILD, heart failure, obesity, lung cancer, and healthy references.
Coordinating Investigator: Magnus Ekström, Region Blekinge.
Uppdaterad: 18 juni 2026
Dela: 
